APL180

DRUG3 trials

Sponsors

Novartis, Novartis Pharmaceuticals

Conditions

Coronary Heart DiseaseFamilial Hypercholesterolemia

Phase 1

Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)

CompletedNCT00568594

NovartisCoronary Heart Disease

Start: 2007-11-30Updated: 2020-12-24

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180

CompletedNCT00907998

Novartis PharmaceuticalsCoronary Heart Disease

Start: 2009-06-30Updated: 2009-11-20

Phase 2

Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients

WithdrawnNCT00751608

Novartis PharmaceuticalsFamilial Hypercholesterolemia

Start: 2006-09-30End: 2009-02-28Updated: 2016-09-23